PI3Kγ in hypertension: a novel therapeutic target controlling vascular myogenic tone and target organ damage

Daniela Carnevale1, Giuseppe Lembo

  • 1Department of Angiocardioneurology, IRCCS Neuromed, Pozzilli, Italy.

Insights

Phosphoinositide 3-kinase gamma (PI3Kγ) regulates blood pressure by controlling vascular myogenic tone. Targeting PI3Kγ offers a promising therapeutic strategy for hypertension and associated organ damage.

Area of Science:

  • Cardiovascular Physiology
  • Molecular Biology
  • Pharmacology

Background:

  • Vascular myogenic response is crucial for blood pressure regulation.
  • Phosphoinositide 3-kinase gamma (PI3Kγ) emerges as a key regulator of vascular tone.
  • Genetic studies link PI3Kγ to blood pressure regulation in human populations.

Purpose of the Study:

  • To review the mechanism of PI3Kγ in controlling blood pressure.
  • To explore PI3Kγ's role in regulating myogenic tone via L-type calcium channels.
  • To assess PI3Kγ as a therapeutic target for hypertension.

Main Methods:

  • Literature review of cellular and molecular mechanisms.
  • Analysis of genetic association studies.
  • Survey of pharmacological approaches and target organ effects.

Main Results:

  • PI3Kγ regulates vascular myogenic tone at the smooth muscle L-type calcium channel level.
  • PI3Kγ is a viable target for antihypertensive therapy.
  • PI3Kγ may mitigate hypertension-induced target organ damage independently of blood pressure reduction.

Conclusions:

  • PI3Kγ is a significant regulator of blood pressure and vascular tone.
  • Targeting PI3Kγ presents a dual therapeutic potential for hypertension and its complications.
  • Further research into PI3Kγ modulation is warranted for novel antihypertensive strategies.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: